ReviewCurrent neurology and neuroscience reports2022
Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers.
Review in Current neurology and neuroscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Isoform-specific steric zippers drive aberrant assembly and mislocalization of shortened TDP-43.Science advances · 2026Article
- A Age Related Vascular Senescence: Mystery of Blood-brain Barrier Dysfunction in Neurodegeneration.Molecular neurobiology · 2026Review
- Molecular signatures and biomarker development for limbic-predominant age-related TDP-43 encephalopathy (LATE).Acta neuropathologica · 2026Review
- Medial temporal lobe Tau-Neurodegeneration mismatch from structural imaging and plasma biomarkers.Brain : a journal of neurology · 2026Article
- Pollutants regulate changes in pathological markers of neurodegenerative diseases: a new perspective in environmental toxicology.Frontiers in toxicology · 2026Review
- Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE)European journal of nuclear medicine and molecular imaging · 2025Article
- Emerging Concepts in Diagnosis, Pathologic Features, and Treatment of Limbic-Predominant Amnestic Neurodegenerative Syndrome (LANS): A Narrative Review.Advances in therapy · 2025Review
- The Biomarker Profile of Alzheimer's Disease for Disease-Modifying Treatment Eligibility: Questions and Debates.International journal of molecular sciences · 2025Review
- New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS.Journal of neuropathology and experimental neurology · 2025Review
- Case Study 8: A 70-Year-Old Man With Memory Loss, Wandering, and Inappropriate Behaviors.The Journal of neuropsychiatry and clinical neurosciences · 2025Article
- Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure ABiomedicines · 2024Article
- How fiber bundle alterations differ in presumed LATE and amnestic Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome.Brain communications · 2024Article
- A limbic-predominant amnestic neurodegenerative syndrome associated with TDP-43 pathology.medRxiv : the preprint server for health sciences · 2023Article
- When Alzheimer's is LATE: Why Does it Matter?Annals of neurology · 2023Review
- Neurodegenerative pathologies associated with behavioral and psychological symptoms of dementia in a community-based autopsy cohort.Acta neuropathologica communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewLimbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently defined neurodegenerative disease characterized by amnestic phenotype and pathological inclusions of TAR DNA-binding protein 43 (TDP-43). LATE is distinct from rarer forms of TDP-43 diseases such as frontotemporal lobar degeneration with TDP-43 but is also a common copathology with Alzheimer's disease (AD) and cerebrovascular disease and accelerates cognitive decline. LATE contributes to clinicopathologic heterogeneity in neurodegenerative diseases, so it is imperative to distinguish LATE from other etiologies. RECENT
findingsNovel biomarkers for LATE are being developed with magnetic resonance imaging (MRI) and positron emission tomography (PET). When cooccurring with AD, LATE exhibits identifiable patterns of limbic-predominant atrophy on MRI and hypometabolism on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.